Caricamento...
Use of bevacizumab in recurrent glioblastoma
Glioblastoma (GBM) is the most common adult primary brain neoplasm. Despite advances in treatment, GBM continues to be associated with considerable morbidity and mortality as compared with other malignancies. Standard treatment for GBM results in survival of 12.9 months (95% CI: 12.3–13.7 months) wi...
Salvato in:
| Pubblicato in: | CNS Oncol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Future Medicine Ltd
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088330/ https://ncbi.nlm.nih.gov/pubmed/25906439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|